Young Investigator Poster Awards
November 7, 2026
Presented below are the winners of the 2026 NEI Fall Congress Young...
Read More
FDA Clears First Digital Therapeutic for Negative Symptoms of Schizophrenia
October 26, 2026
Negative symptoms of schizophrenia, including avolition, anhedonia,...
Read More
Recognizing and Treating ADHD in Adults: An Updated Clinical Review
October 20, 2026
Although traditionally considered a childhood disorder, ADHD freque...
Read More
Orexin-2 Receptor Agonist Shows Preliminary ADHD Symptom Improvement
October 15, 2026
Orexin A and orexin B are neuropeptides produced by neurons concent...
Read More
FDA Approves First Once-Monthly Subcutaneous Olanzapine for Schizophrenia
October 9, 2026
The U.S. Food and Drug Administration (FDA) has approved olanzapine...
Read More
FDA Approves Tavapadon for Adults with Parkinson Disease
October 5, 2026
The U.S. Food and Drug Administration (FDA) has approved tavapadon ...
Read More
Elevating ADHD Awareness Through Clinical Practice
October 1, 2026
October is ADHD Awareness Month. The goal of ADHD Awareness Month i...
Read More
Ketamine Transiently Alters Brain Network Dynamics Linked to Rumination and Somatosensory Processing
September 22, 2026
Ketamine produces rapid antidepressant effects and has been report...
Read More
Eptinezumab Shows Sustained Real-World Benefits in Difficult-to-Treat Migraine
September 19, 2026
Migraine prevention can be particularly challenging in patients wit...
Read More
DT120 Lysergide ODT Receives FDA Breakthrough Therapy Designation for Major Depressive Disorder
September 15, 2026
Definium Therapeutics announced on September 8, 2026, that the US F...
Read More
World Suicide Prevention Day
September 10, 2026
Education matters for suicide prevention. National and regional sui...
Read More
Lithium Treatment May be Associated With Lower Cardiovascular Risk in Bipolar Disorder
September 8, 2026
Lithium remains a first-line treatment with established benefits fo...
Read More